Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science.

Professional Experience: Dr. Hsue trained in Internal Medicine in the Molecular Medicine Training Program at UC San Francisco and in Cardiovascular Medicine at UC San Francisco. She served as Chief Cardiology Fellow during this time. She has been on the faculty in the Department of Medicine at San Francisco General Hospital since 2002. She started the HIV Cardiology Clinic since March 2004 at the Positive Health Program at Ward 86, which is one of the first subspeciality clinics of its kind in the nation.

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco. He also serves as Associate Chief for Research for the ZSFG-UCSF Department of Medicine, Co-Director of the UCSF-GIVI Center for AIDS Research (for basic and translational science), and as a member of the Leadership Committee of the UCSF AIDS Research Institute. He also recently completed terms as Interim Chief of the DEM and Chair of the ACTG Inflammation and End Organ Disease Transformative Science Group.

Dr. Krauss' research program focuses on plasma lipoprotein metabolism and related traits that influence risk for coronary artery disease. His laboratory developed and applied methodology that led to the discovery of a common genetically-influenced atherogenic lipoprotein phenotype that underlies cardiovascular disease risk in patients with obesity, type 2 diabetes, and metabolic syndrome. A major current research emphasis has been the identification of genetic determinants of the wide range of inter-individual variability in phenotypic and clinical response to statin treatment.

Our translational human microbiome research program focuses on gastrointestinal and airway microbiome interactions with host immunity that promote or prevent development/maintenance of chronic inflammatory disease. Taking a "populations to molecules" approach we leverage the microbiome to determine the origins of childhood allergy and asthma and the early life molecular and cellular drivers of immune dysfunction that lead to childhood disease development.